As early as 1992, TBF has been aware of the importance of the use of allogenic bone graft. To that purpose, TBF developed in those years a process of transformation: the PHOENIX process. The latter is unchanged to this day.
The challenge is to provide surgeons with a thoroughly cleaned bone allograft, providing guarantees for security and for fast osseointegration.
The French legislation has gradually been put in place between 1990 and 2000, with the Good Manufacturing Practices, screening tests for infectious diseases and establishment authorizations to which TBF fully complied.
- Early Works: 1992
- Biocompatibility studies: 1993
- Virus inactivation validation: 1995
- Mechanical properties studies: 1993
- First human applications, PHOENIX clinical experience: 1993
- Microbiological safety expert group agreement: 1996
- Phase II , III & IV multicentric Clinical Trials: 1996 to 2008
- "Tissue Bank" Authorization by Afssaps: January 2001
- ISO 9001 - version 2000: April 2003
- Manufacturer of medical devices (TBFIX) complementary to PHOENIX grafts: 2005
- New HQ in Mions, France : 2007
- PHOENIX process authorization: 2010
- ISO 9001 - version 2008: June 2010
- ISO 13485: 2004
- Opening of the TBF Deutschland subsidiary: 2011
- Renewal of the recommendation of the "Haute Autorité de Santé" for reimbursement on top of the T2A ("Tarification à l'acte") - ASR (Improvement in the service rendered) level IV: 2011